Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We thank Pringle et al for their interest and their comments1 concerning our recent article demonstrating how salivary gland epithelial cells (SGECs) from patients with primary Sjögren’s syndrome (pSS) can induce survival and activation of B cells.2 They are rising six very interesting questions:
(1) F Kroese’s group has extensively studied B cells expressing FcRL4 in pSS.3 4 They have shown that this B cell subset is highly proliferating, express activation markers and participates to the formation of lymphoepithelial lesions. Interestingly, they have shown that FcRL4 mRNA was increased in parotid from patients with pSS with mucosa-associaed lymphoid tissue (MALT) lymphoma. FcRL4 could promote innate signalling in response to chronic antigenic stimulation. For all these reasons, it is tempting to speculate that FcRL4+ B cells could be involved in the crosstalk with SGECs.5 We looked at FcRL4 expression in our RNA-seq data set (figure 1A). We did not detect FcRL4 mRNA in blood, nor in salivary gland biopsy. This could be explained by the fact that FcRL4 is likely to be more expressed within parotid3 and our study exclusively involved minor salivary gland biopsies.
(2) Pringle et al wonders about the choice of total circulating B cells in the co-culture. We totally agree that co-culture with specific B cells subsets mainly present within the glands such as FcRL4+ B cells or CD27+ and CD27− B cells would be of interest. But sorting sufficient number of B cells from minor salivary gland that measures around 2–3 mm is, at this time, technically impossible. Plasma cells are another B cell subset infiltrating salivary glands in pSS.6 We tried to differentiate blood B cells into plasmablasts and then performed co-culture with SGECs, but the viability was too low to allow fine assessment of the crosstalk.
(3) Pringle et al wondered why we did not used specific B cells stimulation in our co-culture. However, we made the hypothesis that SGECs could stimulate B cells by themselves without any stimulation, and thus we did not want to artificially stimulate them with the adjunction of cytokines or anti-µ. We used TLR3 stimulation in our co-culture models for mimicking a viral trigger, which could reinforce the ability of SGECs from patients with pSS to increase B-lymphocytes survival.
(4) Pringle et al have carefully analysed the profile of gene expression in SGECs provided in our study. We purified CD326+ SGECs, B lymphocytes, CD4 and CD8 T cells from salivary glands. In spite of this sorting, we found in some SGECs samples, some immunoglobulin genes due to a minor contamination by B cells expressing a high level of immunoglobulins genes. We excluded these samples from the analysis. The level of expression of some immune genes (BTK, CD8a and IGHG1) in SGECs, noticed by Pringle et al, was very low as shown in the figure 1B–D.
(5) Regarding CD326+ epithelial cells, we do agree that they can be either acinar or ductal. Based on the previous work by others on this type of culture,7 we presume that they are rather ductal cells. However, it would be even more interesting if acinar cells that are the effective cells secreting saliva could also activate B cells.
(6) Finally, Pringle et al suggest that the two-dimensional co-culture might be too simplistic. We completely agree. This simple model just allows demonstrating the proof of concept that SGECs are able to activate B cells and that this phenomenon is increased with SGECs from patients with pSS. Development of three-dimensional approaches with organoids is promising. Of note, our group is currently working on a simpler model, which is the culture of a whole minor salivary gland that will also help to unravel from the inside lymphocyte infiltration within salivary glands.8
Handling editor Josef S Smolen
Contributors ER participated in designing the research studies, conducting experiments, acquiring data, analysing data and writing the manuscript.
XM and GN participated in designing the research studies, conducting experiments, analysing data and writing the manuscript
Funding This study was funded by Labex in Research on Medication and Therapeutic Innovation (Grant number: ANR10); Fondation pour la Recherche Médicale (DEQ20150934719); Biogen to Université Paris-Sud (UPSud/SAIC N 97731); Arthritis R&D (CIFRE 2016/1406); Innovative Medicines Initiative 2 Joint Undertaking (NECESSITY grant agreement number 806975).
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Ethics approval This study received approval from the local ethics committee, and informed consent was obtained from all participants.
Provenance and peer review Commissioned; internally peer reviewed.